{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:55:32Z","timestamp":1782896132767,"version":"3.54.5"},"reference-count":14,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.20056","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T22:08:01Z","timestamp":1622844481000},"page":"135-144","source":"Crossref","is-referenced-by-count":10,"title":["Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An                    Observational Database Research Study (CLIMBER-DBR)"],"prefix":"10.3960","volume":"61","author":[{"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[{"name":"Department of Hematology, National Cancer                            Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[{"name":"Innovative Cancer Center, Shimane University                            Hospital, Izumo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and                            Metabolism, Niigata University Faculty of Medicine, Niigata, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Fukase","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Jinushi","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital                            Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Klener                            P. Advances in                    molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci.                    2019; 20: 4417.","DOI":"10.3390\/ijms20184417"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 . The World Health                    Organization classification of malignant lymphomas in Japan: incidence of                    recently recognized entities. Pathol Int. 2000; 50: 696-702.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"3","unstructured":"3 Japanese Society of Hematology. JSH practical                    guidelines for hematological malignancies, 2018, Chapter IV Lymphoma. II                    Lymphoma. 4 Mantle cell lymphoma. Available at:                    http:\/\/www.jshem.or.jp\/gui-hemali\/2_4.html. Accessed March 9, 2020 [in                    Japanese]."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Maruyama                            D,                                Nagai                            H,                                Fukuhara                            N                    <i>et al.<\/i> Final analysis of a phase II study of ibrutinib in                    Japanese patients with relapsed\/refractory mantle cell lymphoma. J Clin Exp                    Hematop. 2019; 59: 98-100.","DOI":"10.3960\/jslrt.19006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Wang                            ML,                                Blum                            KA,                                Martin                            P                    <i>et al.<\/i> Long-term follow-up of MCL patients treated with                    single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126:                    739-745.","DOI":"10.1182\/blood-2015-03-635326"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wang                            ML,                                Rule                            S,                                Martin                            P                    <i>et al.<\/i> Targeting BTK with ibrutinib in relapsed or refractory                    mantle-cell lymphoma. N Engl J Med. 2013; 369: 507-516.","DOI":"10.1056\/NEJMoa1306220"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Goyal                            RK,                                Nagar                            SP,                                Kabadi                            SM                    <i>et al.<\/i> Adverse events, resource use, and economic burden                    associated with mantle cell lymphoma: a real-world assessment of privately                    insured patients in the United States. Leuk Lymphoma. 2019; 60:                    955-963.","DOI":"10.1080\/10428194.2018.1509320"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kabadi                            SM,                                Near                            A,                                Wada                            K,                                Burudpakdee                            C. Treatment                    patterns, adverse events, healthcare resource use and costs among commercially                    insured patients with mantle cell lymphoma in the United States. Cancer Med.                    2019; 8: 7174-7185.","DOI":"10.1002\/cam4.2559"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Smith                            A,                                Roman                            E,                                Appleton                            S                    <i>et al.<\/i> Impact of novel therapies for mantle cell lymphoma in                    the real world setting: a report from the UK\u2019s Haematological Malignancy                    Research Network (HMRN). Br J Haematol. 2018; 181: 215-228.","DOI":"10.1111\/bjh.15170"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Abrahamsson                            A,                                Albertsson-Lindblad                            A,                                Brown                            PN                    <i>et al.<\/i> Real world data on primary treatment for mantle cell                    lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014; 124:                    1288-1295.","DOI":"10.1182\/blood-2014-03-559930"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Abrisqueta                            P,                                Scott                            DW,                                Slack                            GW                    <i>et al.<\/i> Observation as the initial management strategy in                    patients with mantle cell lymphoma. Ann Oncol. 2017; 28:                    2489-2495.","DOI":"10.1093\/annonc\/mdx333"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Cohen                            JB,                                Han                            X,                                Jemal                            A,                                Ward                            EM,                                Flowers                            CR. Deferred                    therapy is associated with improved overall survival in patients with newly                    diagnosed mantle cell lymphoma. Cancer. 2016; 122: 2356-2363.","DOI":"10.1002\/cncr.30068"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Ruan                            J,                                Martin                            P. Which                    patients with mantle cell lymphoma do not need aggressive therapy. Curr Hematol                    Malig Rep. 2016; 11: 234-240.","DOI":"10.1007\/s11899-016-0324-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Martin                            P,                                Chadburn                            A,                                Christos                            P                    <i>et al.<\/i> Outcome of deferred initial therapy in mantle-cell                    lymphoma. J Clin Oncol. 2009; 27: 1209-1213.","DOI":"10.1200\/JCO.2008.19.6121"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/3\/61_20056\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T04:25:43Z","timestamp":1634963143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/3\/61_20056\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20056","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"20056"}}